Viracta Therapeutics, Inc. Announces Scientific Advisory Board Appointments
September 25, 2018 at 08:00 am EDT
Share
Viracta Therapeutics, Inc. announced the formation of its Scientific Advisory Board. The SAB will serve as a strategic resource as Viracta advances therapies based on its kick & kill platform and applies its proprietary epigenetic drug, tractinostat, to enhance cancer immunotherapy. The members of Viracta’s SAB include: Douglas V. Faller, M.D., Ph.D., SAB Chairman; scientific founder for Viracta’s therapeutic approach; former Director Boston University School of Medicine’s Cancer Center and Vice Chairman of the Division of Medicine; Robert Baiocchi, M.D., Ph.D., Professor and Head of the Lymphoma Program at Ohio State University, and member of Blood and Marrow Transplant Clinical Trials Network; Corey Casper, M.D., M.P.H., Chief Medical Officer at Infectious Disease Research Institute (IDRI), and Co-Director of University of Washington/Fred Hutch Center for AIDS Research; Charles Cobbs, M.D., Director of the Ivy Center for Advanced Brain Tumor Treatment in Seattle; pioneered the concept of the potential role of cytomegalovirus in cancer pathogenesis and therapy; Carl June, M.D., Richard W. Vague Professor in Immunotherapy, Department of Pathology and Laboratory Medicine; Director of the Center for Cellular Immunotherapies; Director of Translational Research, Abramson Cancer Center at the University of Pennsylvania; Ronald Levy, M.D., Professor and Director of the Lymphoma Program at Stanford University School of Medicine; Associate Director of Translational Science for the Stanford Cancer Institute; former Chief of the Stanford Division of Medical Oncology; member of the National Academy of Medicine and the National Academy of Sciences; Pierluigi Porcu, M.D., Director of the Hematologic Malignancies and Hematopoietic Stem Cell Transplantation Division in the Department of Medical Oncology for Sidney Kimmel Cancer Center at Thomas Jefferson University; Hao Shen, Ph.D., Professor of Microbiology at Penn Institute for Immunology at University of Pennsylvania bringing expertise in viral models of immune responses and Lawrence Young, Ph.D., Vice President and Director of the Warwick Cancer Research Centre at University of Warwick, UK, distinguished by work in the roles of the Epstein-Barr virus in nasopharyngeal carcinoma and other cancers; Fellow of the UK Academy of Medical Sciences.
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Companyâs lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
VIRACTA THERAPEUTICS, INC. 
